PMID: 8595172Feb 1, 1996Paper

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

British Journal of Cancer
Roger YatesP J Wyld

Abstract

Two multiple-dose studies were conducted in healthy post-menopausal female volunteers to investigate the pharmacokinetics and effects on endocrinology of Arimidex (ZD1033). Volunteers in the first trial were dosed with 3 mg of ZD1033 daily over 10 days to assess the effects on endocrinology of ZD1033 and establish a pharmacokinetic profile. In the second trial volunteers received 14 daily doses of either 0.5 or 1.0 mg of ZD1033 to assess the pharmacokinetics of ZD1033 and the effects of low doses of ZD1033 on serum oestradiol concentrations. Following multiple dosing a significant reduction in the concentration of serum oestradiol of approximately 80% of baseline was obtained with all three doses; no recovery in oestradiol was apparent for up to 144 h after the last dose. There was no overall difference in the level of oestradiol suppression between the 0.5 or 1.0 mg doses of ZD1033. However, comparison of the number of volunteers with oestradiol concentrations below the limits of detection of the assay, 24 h after the last dose of ZD1033, suggested that 1.0 mg was the minimal dose required for maximal suppression of oestradiol. No significant effect was recorded on serum concentrations of gonadotrophins over the dosing period....Continue Reading

Citations

Oct 31, 1998·Breast Cancer Research and Treatment·P E LønningM Dowsett
Feb 28, 2003·Expert Opinion on Investigational Drugs·W R Miller, J Jackson
Dec 8, 2006·Expert Opinion on Pharmacotherapy·J Michael Dixon
Oct 2, 2009·Clinical Medicine. Therapeutics·Monica MilaniDavid A Potter
May 19, 2012·Expert Opinion on Pharmacotherapy·Abdullah Turkistani, Sharon Marsh
Jul 4, 2002·Annals of the New York Academy of Sciences·Shiuan ChenBin Yu
Oct 5, 2001·Expert Opinion on Pharmacotherapy·S Iqbal, W R Miller
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea DecensiBernardo Bonanni
Oct 17, 2012·BMC Cancer·Anne S OberguggenbergerMichael Hubalek
Jun 1, 2002·Drugs & Aging·Per E Lønning
Aug 9, 2003·Expert Opinion on Drug Safety·J JacksonJ M Dixon
Feb 21, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y F LiJ J Kavanagh
Nov 4, 2010·Breast Cancer Research and Treatment·G J van LondenS L Greenspan
Oct 7, 2010·Expert Opinion on Drug Safety·Catherine M Kelly, Aman U Buzdar
Nov 8, 2002·Drugs·Keri Wellington, Diana M Faulds
Apr 7, 2004·Journal of the American Geriatrics Society·Amit Arora, Jane F Potter
Jul 27, 2006·Expert Opinion on Drug Metabolism & Toxicology·Raimund Jakesz
Oct 31, 1998·Breast Cancer Research and Treatment·M Dowsett
Jul 8, 2003·Clinical Pharmacokinetics·Per Lønning
Aug 21, 2002·Breast Cancer Research and Treatment·Robert W Brueggemeier
Apr 16, 1998·American Journal of Clinical Oncology·A U Buzdar
Mar 10, 2019·The Journal of Steroid Biochemistry and Molecular Biology·Priya BhardwajKristy A Brown
Aug 26, 1998·The Journal of Steroid Biochemistry and Molecular Biology·A M Brodie, V C Njar
Jun 19, 2001·Molecular and Cellular Endocrinology·G Séralini, S Moslemi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Steroid Biochemistry and Molecular Biology
P V PlourdeA Webster
Gan to kagaku ryoho. Cancer & chemotherapy
Shigeto MiuraMinoru Tsuboi
© 2021 Meta ULC. All rights reserved